Abstract 218P
Background
Adenosine (ADO) is a major immunosuppressive player within the tumor micro-environment (TME), acting via A2A and A2B receptors or through the equilibrative nucleoside transporter 1 (ENT1). Quantifying ADO in the TME could help identify tumors more likely to respond to the several ADO pathway-targeting agents that have entered clinical trials. However, several limitations make ADO measurement impractical. Gene signatures have been proposed to overcome this limitation, but none truly reflects ADO content in the TME. Here, we present the first ADO gene signature based on spatial ADO quantification in human tumors and demonstrate its potential for indication selection.
Methods
Thirteen tumor biopsies from six cancer types were analyzed for ADO using quantitative mass spectrometry imaging (qMSI). A total of 183 regions of interest (ROIs) were selected based on ADO content (high vs low) and profiled by spatial transcriptomics (GeoMx DSP). ROIs were split into training (70%) and test (30%) sets. A linear mixed model adjusted for tumor type and patient was applied to the training set to identify differentially expressed genes (DEGs) in high vs low ADO regions (FDR <0.05). g:profiler was used to perform pathway enrichment. Lasso regression identified the most predictive DEGs, and the resulting gene signature predictive accuracy was evaluated using the Area Under the Receiver Operating Characteristics (AUROC) on the test set.
Results
We identified 249 DEGs when comparing high vs low ADO ROIs across tumor types. Pathway enrichment analysis revealed associations with metabolism and immune activation. Twenty-five DEGs had the highest cross-tumor predictive power, as validated in the test set (AUC = 0.905). In TCGA, the new ADO signature was higher in tumors compared to healthy tissue and showed variable expression and prognostic value across tumor subtypes.
Conclusions
We developed the first ADO signature based on ADO content in human tumors. The novel signature is a powerful tool to prioritize indications that would benefit the most from ADO-targeting drugs, and holds potential to unveil the mechanisms of ADO immunosuppression and to identify individual patients responsive to treatment.
Legal entity responsible for the study
iTeos Therapeutics.
Funding
iTeos Therapeutics.
Disclosure
S. Dekoninck, N. Rosewick, T. Sanders, L. Chaible, J. Marchante, H. Shehade, F. Strozzi, E. Houthuys, Y. McGrath, R. Marillier, M. Rossetti: Financial Interests, Personal, Full or part-time Employment: iTeos Therapeutics; Financial Interests, Personal, Stocks/Shares: iTeos Therapeutics. C. Martinoli: Financial Interests, Personal, Advisory Role: iTeos Therapeutics.
Resources from the same session
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract